🇺🇸 FDA
Patent

US 11072792

Materials and methods for treatment of usher syndrome type 2A

granted A61PA61P27/00

Quick answer

US patent 11072792 (Materials and methods for treatment of usher syndrome type 2A) held by CRISPR THERAPEUTICS AG expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P27/00